Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

Author

Jen Farmer

This email address is being protected from spambots. You need JavaScript enabled to view it.

Chief Executive Officer

Title Created Date Category
Horizon Pharma plc Completes Target Enrollment of 90 Patients for Phase 3 Trial of ACTIMMUNE(R) (interferon gamma-1b) for the Treatment of People With Friedreich's Ataxia Thursday, May 5, 2016 Scientific News
Frataxin and the molecular mechanism of mitochondrial iron-loading in Friedreich's ataxia Monday, May 2, 2016 Scientific News
Time-resolved functional analysis of acute impairment of frataxin expression in an inducible cell model of Friedreich ataxia Tuesday, April 26, 2016 Scientific News
Two different pathogenic mechanisms, dying-back axonal neuropathy and pancreatic senescence, are present in the YG8R mouse model of Friedreich ataxia Tuesday, April 19, 2016 Scientific News
Development of an AAV9 coding for a 3XFLAG-TALEfrat#8-VP64 able to increase in vivo the human frataxin in YG8R mice Monday, April 18, 2016 Scientific News
Comorbid Medical Conditions in Friedreich Ataxia: Association With Inflammatory Bowel Disease and Growth Hormone Deficiency Friday, April 15, 2016 Funded Research
Lymphoblast Oxidative Stress Genes as Potential Biomarkers of Disease Severity and Drug Effect in Friedreich's Ataxia Friday, April 15, 2016 Scientific News
Effects of Genetic Severity on Glucose Homeostasis in Friedreich Ataxia Tuesday, April 12, 2016 Funded Research
Using human pluripotent stem cells to study Friedreich ataxia cardiomyopathy Monday, April 4, 2016 Funded Research
Gastrocnemius and soleus spasticity and muscle length in Friedreich's ataxia Monday, April 4, 2016 Funded Research

SHARE

FacebookTwitterLinkedInYoutube
Family A.jpg
Site Map     Privacy Policy     Service Terms     Log-in     Contact     Charity Navigator